Aurinia Pharmaceuticals

Hope springs for April inhibition
Hope springs for April inhibition
EP Vantage
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
Flag link:
3 Biotechs That Might Get Bought Out in 2023
3 Biotechs That Might Get Bought Out in 2023
Motley Fool
M&A
Madrigal Pharmaceuticals
Amylyx
Aurinia Pharmaceuticals
Flag link:
Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug
Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug
Medical Dialogues
Aurinia Pharmaceuticals
Sun Pharma
dry eye disease
Cequa
Flag link:
Two Aurinia execs are out — and CRISPR’s operations chief isn't far behind
Two Aurinia execs are out — and CRISPR’s operations chief isn't far behind
Endpoints
Aurinia Pharmaceuticals
CRISPR Therapeutics
Flag link:
Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook
Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook
Investors Business Daily
Aurinia Pharmaceuticals
earnings
Lupkynis
Flag link:
What to Expect From Biogen's $2.3 Billion Shopping Spree
What to Expect From Biogen's $2.3 Billion Shopping Spree
Motley Fool
Biogen
M&A
Aurinia Pharmaceuticals
Biohaven
Flag link:
Biotech investors pray for a takeover miracle
Biotech investors pray for a takeover miracle
EP Vantage
M&A
biotech
Amylyx Pharmaceuticals
Arena Pharmaceuticals
AstraZeneca
Aurinia Pharmaceuticals
Biogen
Biohaven
Bristol Myers Squibb
Eli Lilly
GSK
Merck
Novartis
Novo Nordisk
Pfizer
Sanofi
Flag link:
Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?
Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?
Motley Fool
Bristol Myers Squibb
Aurinia Pharmaceuticals
M&A
Flag link:
What Novartis could buy with its windfall
What Novartis could buy with its windfall
EP Vantage
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Flag link:
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
Motley Fool
Bristol Myers Squibb
Aurinia Pharmaceuticals
M&A
Flag link:
Acquisition Rumors Continue to Circulate Around Aurinia as GSK Denies Interest
Acquisition Rumors Continue to Circulate Around Aurinia as GSK Denies Interest
BioSpace
GSK
Aurinia Pharmaceuticals
M&A
Flag link:
2 Biotech Stocks That Could Go Parabolic This Week
2 Biotech Stocks That Could Go Parabolic This Week
Motley Fool
biotech
biotech stocks
Aurinia Pharmaceuticals
M&A
Ocugen
Covaxin
vaccines
COVID-19
Flag link:
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout
Fierce Pharma
Bristol Myers Squibb
Acceleron
M&A
Aurinia Pharmaceuticals
Flag link:
Eight Months After First FDA Approval, Aurinia Picks Up Two More Candidates
Eight Months After First FDA Approval, Aurinia Picks Up Two More Candidates
BioSpace
Aurinia Pharmaceuticals
autoimmune disease
Thunderbolt Pharma
M&A
Flag link:
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Motley Fool
Pfizer
M&A
Blueprint Medicines
Aurinia Pharmaceuticals
Atea Pharmaceuticals
Flag link:
Fortunes diverge for solo drug launchers
Fortunes diverge for solo drug launchers
EP Vantage
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Flag link:
Catalent signs on to produce Aurinia's newly approved lupus nephritis drug
Catalent signs on to produce Aurinia's newly approved lupus nephritis drug
Fierce Pharma
Catalent
Aurinia Pharmaceuticals
lupus nephritis
Lupkynis
CDMOs
Flag link:
Here’s Why the Approval of Lupkynis Has Biotech Investors Buzzing
Here’s Why the Approval of Lupkynis Has Biotech Investors Buzzing
Xtalks
FDA
Aurinia Pharmaceuticals
Lupkynis
voclosporin
lupus nephritis
Flag link:
After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
Endpoints
Aurinia Pharmaceuticals
lupus nephritis
GSK
Otsuka
Benlysta
Flag link:
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS
Flag link:

Pages